These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 28069548)
1. Long noncoding RNA HULC promotes cell proliferation by regulating PI3K/AKT signaling pathway in chronic myeloid leukemia. Lu Y; Li Y; Chai X; Kang Q; Zhao P; Xiong J; Wang J Gene; 2017 Apr; 607():41-46. PubMed ID: 28069548 [TBL] [Abstract][Full Text] [Related]
2. LncRNA highly upregulated in liver cancer regulates imatinib resistance in chronic myeloid leukemia via the miR-150-5p/MCL1 axis. Han Y; Ma Z Anticancer Drugs; 2021 Apr; 32(4):427-436. PubMed ID: 33587348 [TBL] [Abstract][Full Text] [Related]
3. The role of long noncoding RNA HOTAIR in the acquired multidrug resistance to imatinib in chronic myeloid leukemia cells. Wang H; Li Q; Tang S; Li M; Feng A; Qin L; Liu Z; Wang X Hematology; 2017 May; 22(4):208-216. PubMed ID: 27875938 [TBL] [Abstract][Full Text] [Related]
4. ZFX Facilitates Cell Proliferation and Imatinib Resistance in Chronic Myeloid Leukemia Cells. Wu J; Wei B; Wang Q; Ding Y; Deng Z; Lu X; Li Y Cell Biochem Biophys; 2016 Jun; 74(2):277-83. PubMed ID: 26912059 [TBL] [Abstract][Full Text] [Related]
5. HULC long noncoding RNA silencing suppresses angiogenesis by regulating ESM-1 via the PI3K/Akt/mTOR signaling pathway in human gliomas. Zhu Y; Zhang X; Qi L; Cai Y; Yang P; Xuan G; Jiang Y Oncotarget; 2016 Mar; 7(12):14429-40. PubMed ID: 26894862 [TBL] [Abstract][Full Text] [Related]
6. LncRNA HULC promotes non-small cell lung cancer cell proliferation and inhibits the apoptosis by up-regulating sphingosine kinase 1 (SPHK1) and its downstream PI3K/Akt pathway. Liu L; Zhou XY; Zhang JQ; Wang GG; He J; Chen YY; Huang C; Li L; Li SQ Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8722-8730. PubMed ID: 30575912 [TBL] [Abstract][Full Text] [Related]
7. The Critical Role of PTEN/PI3K/AKT Signaling Pathway in Shikonin-Induced Apoptosis and Proliferation Inhibition of Chronic Myeloid Leukemia. Chen Y; Wang T; Du J; Li Y; Wang X; Zhou Y; Yu X; Fan W; Zhu Q; Tong X; Wang Y Cell Physiol Biochem; 2018; 47(3):981-993. PubMed ID: 29843123 [TBL] [Abstract][Full Text] [Related]
8. Silencing of miR-21 sensitizes CML CD34+ stem/progenitor cells to imatinib-induced apoptosis by blocking PI3K/AKT pathway. Wang WZ; Pu QH; Lin XH; Liu MY; Wu LR; Wu QQ; Chen YH; Liao FF; Zhu JY; Jin XB Leuk Res; 2015 Oct; 39(10):1117-24. PubMed ID: 26248946 [TBL] [Abstract][Full Text] [Related]
9. Long non-coding RNA HULC promotes bladder cancer cells proliferation but inhibits apoptosis via regulation of ZIC2 and PI3K/AKT signaling pathway. Wang J; Ma W; Liu Y Cancer Biomark; 2017 Dec; 20(4):425-434. PubMed ID: 28946549 [TBL] [Abstract][Full Text] [Related]
10. Simvastatin potentiates the cell-killing activity of imatinib in imatinib-resistant chronic myeloid leukemia cells mainly through PI3K/AKT pathway attenuation and Myc downregulation. Ding L; Chen Q; Chen K; Jiang Y; Li G; Chen Q; Bai D; Gao D; Deng M; Zhang H; Xu B Eur J Pharmacol; 2021 Dec; 913():174633. PubMed ID: 34843676 [TBL] [Abstract][Full Text] [Related]
11. Stellettin B induces apoptosis in human chronic myeloid leukemia cells via targeting PI3K and Stat5. Chen Y; Zhou Q; Zhang L; Zhong Y; Fan G; Zhang Z; Wang R; Jin M; Qiu Y; Kong D Oncotarget; 2017 Apr; 8(17):28906-28921. PubMed ID: 28423649 [TBL] [Abstract][Full Text] [Related]
12. HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells. Sugimoto Y; Nakamura S; Okinaka K; Hirano I; Ono T; Shigeno K; Shinjo K; Ohnishi K Leuk Res; 2008 Jun; 32(6):962-71. PubMed ID: 18190961 [TBL] [Abstract][Full Text] [Related]
13. The c-Myc-regulated lncRNA NEAT1 and paraspeckles modulate imatinib-induced apoptosis in CML cells. Zeng C; Liu S; Lu S; Yu X; Lai J; Wu Y; Chen S; Wang L; Yu Z; Luo G; Li Y Mol Cancer; 2018 Aug; 17(1):130. PubMed ID: 30153828 [TBL] [Abstract][Full Text] [Related]
14. Extracellular vesicle-mediated regulation of imatinib resistance in chronic myeloid leukemia via the miR-629-5p/SENP2/PI3K/AKT/mTOR axis. Jiang Y; Xiao S; Huang S; Zhao X; Ding S; Huang Q; Xiao W; Li Z; Zhu H Hematology; 2024 Dec; 29(1):2379597. PubMed ID: 39056503 [TBL] [Abstract][Full Text] [Related]
15. MicroRNA-7 inhibits cell proliferation of chronic myeloid leukemia and sensitizes it to imatinib in vitro. Jiang MJ; Dai JJ; Gu DN; Huang Q; Tian L Biochem Biophys Res Commun; 2017 Dec; 494(1-2):372-378. PubMed ID: 28986256 [TBL] [Abstract][Full Text] [Related]
16. A long noncoding RNA critically regulates Bcr-Abl-mediated cellular transformation by acting as a competitive endogenous RNA. Guo G; Kang Q; Zhu X; Chen Q; Wang X; Chen Y; Ouyang J; Zhang L; Tan H; Chen R; Huang S; Chen JL Oncogene; 2015 Apr; 34(14):1768-79. PubMed ID: 24837367 [TBL] [Abstract][Full Text] [Related]
17. Expression differences of genes in the PI3K/AKT, WNT/b-catenin, SHH, NOTCH and MAPK signaling pathways in CD34+ hematopoietic cells obtained from chronic phase patients with chronic myeloid leukemia and from healthy controls. de Cássia Viu Carrara R; Fontes AM; Abraham KJ; Orellana MD; Haddad SK; Palma PVB; Panepucci RA; Zago MA; Covas DT Clin Transl Oncol; 2018 Apr; 20(4):542-549. PubMed ID: 28905209 [TBL] [Abstract][Full Text] [Related]
18. TAL1 mediates imatinib-induced CML cell apoptosis via the PTEN/PI3K/AKT pathway. Wu Y; Hu Y; Yu X; Zhang Y; Huang X; Chen S; Li Y; Zeng C Biochem Biophys Res Commun; 2019 Nov; 519(2):234-239. PubMed ID: 31493871 [TBL] [Abstract][Full Text] [Related]
19. LncRNA MALAT1 promotes cell proliferation and imatinib resistance by sponging miR-328 in chronic myelogenous leukemia. Wen F; Cao YX; Luo ZY; Liao P; Lu ZW Biochem Biophys Res Commun; 2018 Dec; 507(1-4):1-8. PubMed ID: 30366670 [TBL] [Abstract][Full Text] [Related]
20. Long non-coding RNA small nucleolar RNA host gene 29 drives chronic myeloid leukemia progression via microRNA-483-3p/Casitas B-lineage Lymphoma axis-mediated activation of the phosphoinositide 3-kinase/Akt pathway. Feng X; Yang L; Liu X; Liu M; Liu L; Liu J; Luo J Med Oncol; 2024 Jan; 41(2):60. PubMed ID: 38252204 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]